Table 2 Baseline patient characteristics
RCT CZP (n = 1224) | All CZP (n = 1506) | ||
|---|---|---|---|
Female sex, n (%) | 1008 (82.4) | 1245 (82.7) | |
Age, years, n (%) | <50 | 470 (38.4) | 580 (38.5) |
≥50 to < 60 | 440 (35.9) | 546 (36.3) | |
≥60 to < 70 | 247 (20.2) | 300 (19.9) | |
≥70 | 67 (5.5) | 80 (5.3) | |
Disease duration (years), n (%) | <2 | 261 (21.3) | 323 (21.4) |
≥2 | 963 (78.7) | 1183 (78.6) | |
DAS28(CRP), mean (SD) | 6.20 (0.83) | 6.20 (0.85) | |
HAQ-DI, mean (SD) | 1.65 (0.60) | 1.65 (0.60) | |
CRP, mg/L, median (IQR) | 15.0 (6.0–32.0) | 15.0 (6.0–32.0) | |
Rheumatoid factor, IU/ml, median (IQR) | 68.3 (18.9–201.1) | 70.0 (19.4–200.0) | |
mTSS, median (IQR) | 20.0 (5.5–54.7) | 20.0 (6.0–55.0) | |
BMI, kg/m2, n (%) | <20 | 83 (6.8) | 104 (6.9) |
20–30 | 833 (68.1) | 1024 (68.0) | |
>30 | 308 (25.2) | 378 (25.1) | |
Glucocorticoid dose, mg/day, n (%) | 0 | 518 (42.3) | 637 (42.3) |
>0–5 | 332 (27.1) | 402 (26.7) | |
>5 | 374 (30.6) | 467 (31.0) | |
Systemic MTX dose, mg/week, n (%) | ≤15 | 1018 (83.2) | 1261 (83.7) |
>15 | 206 (16.8) | 245 (16.3) | |
Medically treated comorbidities, n (%)a | |||
Diabetes mellitus | 47 (3.8) | 53 (3.5) | |
COPD/asthma | 34 (2.8) | 38 (2.5) | |
Cardiac disorderb | 15 (1.2) | 17 (1.1) | |
Hypertensionc | 387 (31.6) | 465 (30.9) | |
Hyperlipidemia | 55 (4.5) | 66 (4.4) | |
Thyroid disorder | 55 (4.5) | 63 (4.2) | |
Osteoporosis | 92 (7.5) | 113 (7.5) | |
Depression | 37 (3.0) | 45 (3.0) | |